US 8,653,263 · Application 13/503,231 · Granted Feb 18, 2014
US 8,653,263
Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
Estimated expiration
October 21, 2030
4y 25d remaining
Earliest effective filing
Oct 21, 2010
+ 20 years
Oct 21, 2030
PTA +0d
Oct 21, 2030
No TD
—
Final
Oct 21, 2030
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- April 20, 2012
- Earliest effective filing
- October 21, 2010
- Issue date
- February 18, 2014
- PTA
- 0 days
- Base expiry (before PTA)
- October 21, 2030
October 21, 2010 + 20 years = October 21, 2030
- National stage entry of application PCTUS2010053606, filed Oct 21, 2010
- PRO61/254,509 — Provisional — not used for base term
- PRO61/254,509 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 13/503,231 · US 8,653,263
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 8,653,263: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8653263Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.